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Indianapolis, Indiana; Boston, Massachusetts; and Santa Clara, CaliforniaObjectives This study sought to evaluate the long-term safety and efﬁcacy of everolimus-eluting
stents (EES) and paclitaxel-eluting stents (PES) in patients with obstructive coronary artery disease.
Background The use of EES compared to PES has been shown to result in improved clinical outcomes
in patients undergoing PCI. However, there have been concerns regarding the durability of these
beneﬁts over longer-term follow-up.
Methods SPIRIT III was a prospective, multicenter trial in which 1,002 patients were randomized 2:1 to
EES versus PES. Endpoints included ischemia-driven target vessel failure (TVF) (death, myocardial
infarction (MI), or ischemia-driven target vessel revascularization [TVR]), the pre-speciﬁed primary
endpoint), target lesion failure (TLF) (cardiac death, target-vessel MI, or ischemia-driven target lesion
revascularization [TLR]), major adverse cardiac events (MACE) (cardiac death, MI, or ischemia-driven
TLR), their individual components and stent thrombosis.
Results Five-year follow-up was available in 91.9% of patients. Treatment with EES versus PES
resulted in lower 5-year Kaplan-Meier rates of TVF (19.3% vs. 24.5%, p ¼ 0.05), TLF (12.7% vs. 19.0%,
p ¼ 0.008), and MACE (13.2% vs. 20.7%, p ¼ 0.007). EES also resulted in reduced rates of all-cause
death (5.9% vs. 10.1%, p ¼ 0.02), with nonsigniﬁcantly different rates of MI, stent thrombosis, and TLR,
and no evidence of late catch-up of TLR over time.
Conclusions At 5 years after treatment, EES compared to PES resulted in durable beneﬁts in
composite safety and efﬁcacy measures as well as all-cause mortality. Additionally, the absolute
difference in TLR between devices remained stable over time without deterioration of effect during
late follow-up. (J Am Coll Cardiol Intv 2013;6:1263–6) ª 2013 by the American College of Cardiology
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1264Drug-eluting stents (DESs) preserve the mechanical
advantages of bare-metal stents, providing greater acute
luminal gain compared with balloon angioplasty, although
concerns have arisen regarding the long-term beneﬁts of
DESs due to observations of late stent thrombosis and
increases in target lesion revascularization (TLR) over time.
To properly evaluate the comparative risks and beneﬁts
of DESs, clinical outcomes must be examined over longer-
term follow-up than is required for initial device approval.
The SPIRIT III (Clinical Evaluation of the XIENCE V
Everolimus Eluting Coronary Stent System in the Treat-
ment of Patients with De Novo Native Coronary Artery
Lesions) trial, the pivotal approval trial for the XIENCE V
(Abbott Vascular, Santa Clara, California) DES in the
United States, randomized patients with symptomatic,
noncomplex coronary artery disease to TAXUS EXPRESS2
paclitaxel-eluting stents (PESs) (Boston Scientiﬁc, Natick,
Massachusetts) or XIENCE V everolimus-eluting stents
(EESs) (1). In the SPIRIT III, treatment with EESsAbbreviations
and Acronyms
DES = drug-eluting stent(s)
EES = everolimus-eluting
stent(s)




TLF = target lesion failure
TLR = target lesion
revascularization
TVF = target vessel failurewas associated with a signiﬁcant
reduction in the amount of in-
segment late loss at 8 months (the
primary angiographic endpoint),
as well as noninferiority with
respect to the primary clinical
endpoint of target vessel failure
(TVF) at 9 months. Given the
paucity of long-term data on the
safety and efﬁcacy of DESs, we
performed a 5-year follow-up
analysis of the SPIRIT III trial.MethodsThe SPIRIT III trial was a prospective, multicenter,
randomized, single-blind, controlled clinical trial in which
1,002 patients with either 1 or 2 de novo native coronary
artery lesions (maximum of 1 lesion per epicardial coronary
artery) were randomized in a 2:1 ratio to receive the ever-
olimus-eluting XIENCE V stent (Abbott Vascular) or the
paclitaxel-eluting TAXUS EXPRESS2 stent (Boston
Scientiﬁc). The trial’s inclusion and exclusion criteria,
protocol, primary and pre-speciﬁed clinical endpoints are as
described in the primary publication (1). Statistical analysis
for the 5-year follow-up were similar to that performed for
the 2- and 3-year follow-up analyses of the SPIRIT III and
performed using SAS version 9.1.3 (SAS Institute, Cary,
North Carolina) (2,3).Results
Between June 2005 and March 2006, a total of 1,002
patients were randomized at 65 U.S. sites to receive the EES(n ¼ 669) or the PES (n ¼ 332). Baseline characteristics for
the 2 well-matched groups were as reported previously
(1–3). Antiplatelet agent use at 5-year follow-up was not
signiﬁcantly different with regard to use of aspirin (89.6%
in the EES group vs. 93.2% in the PES group, p ¼ 0.10) or
a thienopyridine (44.2% in the EES group vs. 44.0% in the
PES group, p ¼ 0.99). Follow-up through 5 years was
completed in 91.9% (921 of 1,002) of patients, including
92.8% (621 of 669) of patients receiving EESs and 90.9%
(300 of 333) of patients receiving PESs. Rates of major
clinical endpoints at 5 years are represented in Figure 1 and
Online Table 1. EESs resulted in a lower incidence of the
primary composite endpoint of TVF (19.3% vs. 24.5% in
the PES group, p ¼ 0.05). Compared with 1 year, at which
time the EES was associated with an absolute 2.5% lower
rate of TVF compared with the PES, at 5 years the absolute
difference between stent types had increased to 5.2%.
Additionally, the EES resulted in signiﬁcantly lower 5-year
rates of target-lesion failure (TLF) (12.7% vs. 19.0%, p ¼
0.008) and major adverse cardiovascular events (MACE)
(13.7% vs. 20.2%, p ¼ 0.007). There was a trend present
toward a lower 5-year rate of ischemia-driven TLR with the
EES compared with the PES (8.6% vs. 12.1%, p ¼ 0.08).
The difference between EES and PES in the rate of
ischemia-driven TLR between year 1 and year 5 was stable
or slightly increasing (absolute difference of 2.1% favoring
the EES at year 1; absolute difference of 3.5% favoring the
EES at year 5). All-cause mortality at 5 years was signiﬁ-
cantly lower with the EES compared with the PES (5.9%
vs. 10.1%, p ¼ 0.02), representing a 43% relative reduction
in the risk of death. After 1 year, very late Advanced
Research Consortium deﬁnite/probable stent thrombosis
occurred in 0.5% of EES-treated patients compared with
1.0% of PES-treated patients (p ¼ 0.36) (Online Table 2).
The interactions between treatment assignment and
important subgroups with regard to the primary endpoint of
TVF were evaluated in pre-speciﬁed subgroups with
borderline signiﬁcant interactions present with respect to age
(p ¼ 0.05) and sex (p ¼ 0.03). The interaction between
randomized treatment group and diabetic status was not
signiﬁcant (p ¼ 0.20), although diabetic patients had similar
5-year rates of TVF with each type of stent (22.9% with the
EES vs. 23.0% with the PES).
Discussion
The principal ﬁndings of the 5-year analysis from the
multicenter, randomized SPIRIT III trial are the
following: 1) compared with the PES, treatment with the
EES resulted in lower 5-year rates of the composite safety
and efﬁcacy endpoints of TVF, TLF, and MACE; 2) all-
cause mortality was also reduced at 5 years in patients
treated with the EES compared with the PES; 3) the 5-
year rates of myocardial infarction, stent thrombosis, and
Figure 1. Time-to-Event Curves Through 5 Years
Time-to-event curves of TVF (A), TLF (B), ischemia-driven TLR (C), and all-cause death (D). EES ¼ everolimus-eluting stent(s); HR ¼ hazard ratio; PES ¼ paclitaxel-eluting
stent(s); TLF ¼ target lesion failure; TLR ¼ target lesion revascularization; TVF ¼ target vessel failure.
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between the EES and the PES in the present trial; and 4)
there was no apparent erosion in the relative magnitude of
TLR with the EES compared with the PES during the 5-
year follow-up period.
Study limitations. The SPIRIT III was powered for non-
inferiority between the EES and the PES for the endpoint
of TVF at 9-month follow-up. The results of the present
study should thus be considered hypothesis generating,
especially concerning differences in low-frequency clinical
endpoints and subgroups.Conclusions
The present 5-year analysis represents the longest assess-
ment of outcomes with the EES and the PES to date.
Larger clinical studies comparing the EES with the PES
were subsequently performed, albeit with shorter durations
of follow-up. In the SPIRIT IV trial (N ¼ 3,687),
the primary endpoint of TLF at 1-year was signiﬁcantlylower with the EES compared with the PES (4.2% vs.
6.9%, p < 0.001) (4). The COMPARE (Second-
Generation Everolimus-Eluting and Paclitaxel-Eluting
Stents in Real-Life Practice) trial also demonstrated
signiﬁcantly lower rates of MACE (deﬁned as all-cause
mortality, myocardial infarction, or clinically driven TVR)
at 1-year with the EES compared with the PES (6.2% vs.
9.1%, p ¼ 0.02) (5). Follow-up to 2 years has been
completed in these trials and conﬁrmed the beneﬁts of the
EES over the PES at this time point. The present analysis,
extending these ﬁndings to 5 years, conﬁrms the durability
of the safety and effectiveness of the EES compared with
the PES with regard to the primary clinical outcome
of TVF.
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